Geneva, Switzerland, Juy 24, 2020 – The joint project will allow the company to further characterize the effect of blocking JAM-C (Junction Adhesion Molecule C) in hematological malignancies. The project, to be conducted in collaboration with the Geneva University Hospitals (HUG), will receive over 500,000 CHF in the form of a grant.
top of page
Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...
Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...
Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...
bottom of page
댓글